PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
ProQR Therapeutics N.V.
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 12, 2026
$1.31+0.00 (0.00%)
Close on Oct 19, 2026
ProQR Therapeutics statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Market Cap | €123.31M | €911.72M |
| Enterprise Value | €35.77M | €858.97M |
| PS Ratio | 7.75 | 7.36 |
| PB Ratio | 2.50 | 1.21 |
| P/TBV Ratio | 2.50 | 2.50 |
Enterprise value
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 2.25 | 3.57 |
Income (trailing twelve months)
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Revenue | €15.91M | €447.40M |
| Operating Income | -€43.45M | -€68.03M |
| Pretax Income | -€42.17M | -€49.18M |
| Net Income | -€42.18M | -€6.53M |
| EBITDA | -€43.45M | -€48.04M |
| EPS (Diluted) | -0.40 EUR | -0.61 EUR |
Margins
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -273.1% | -33.2% |
| Pretax Margin | -265.1% | -36.6% |
| Profit Margin | -265.2% | -31.7% |
| EBITDA Margin | -273.1% | -28.6% |
| FCF Margin | -338.3% | -24.4% |
Returns
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -61.2% | 2.67% |
| Return on Assets (ROA) | -30.1% | -5.10% |
| Return on Capital Employed (ROCE) | -54.1% | -26.9% |
Growth
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -15.9% | 1.99% |
| Revenue Growth (3Y CAGR) | 64.2% | 13.5% |
Balance sheet
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €92.41M | €291.68M |
| Total Debt | €4.87M | €496.91M |
| Net Cash (Debt) | €87.54M | €87.54M |
| Net Cash Per Share | 0.83 EUR | 1.09 EUR |
| Equity (Book Value) | €49.37M | €952.53M |
| Book Value Per Share | 0.47 EUR | 5.36 EUR |
| Tangible Book Value | €49.37M | €21.84M |
| Working Capital | €67.69M | €121.78M |
Financial position
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.09 | 2.81 |
| Quick Ratio | 3.06 | 1.23 |
| Debt / Equity | 0.10 |
Cash flow (trailing twelve months)
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -€52.79M | -€35.31M |
| Capital Expenditures | -€1.02M | -€4.42M |
| Free Cash Flow | -€53.81M | -€53.81M |
| FCF Per Share | -0.51 EUR | -0.56 EUR |
Efficiency
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.11 | 0.32 |
| Revenue Per Employee | €269.59K | €819.26K |
| Profits Per Employee | -€714.98K | -€247.02K |
| Employee Count | 59 | 378 |
Dividends and yields
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -34.2% | -1.79% |
| FCF Yield | -43.6% | -13.4% |
Shares
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 105,361,000 | 105,361,000 |
| Shares Change (YoY) | 22.4% | 6.28% |
| Float | 65,525,700 | 78,574,400 |
| Shares Held by Insiders | 37.8% | 9.05% |
Taxes
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Income Tax | €19.00K | €1.53M |
Scores
| Measure | ProQR Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -5.05 | 1.02 |
| Piotroski F-Score | 1 | 5 |
Calculated by StockData from ProQR Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.